E2F1 activity in triple-negative breast cancer patients is clinically relevant, as one study showed that patients that respond to doxorubicin treatment had upregulated E2F1 in tumor biopsies and non-responders did not [30]. Here, E2F1 is linked to triple-negative breast carcinoma.